Clinical characteristics and prognostic implications of diabetes and myocardial injury in patients admitted to the emergency room.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
30 08 2021
Historique:
received: 27 05 2021
accepted: 23 08 2021
entrez: 31 8 2021
pubmed: 1 9 2021
medline: 22 12 2021
Statut: epublish

Résumé

This study aimed to investigate the clinical features and prognosis of diabetes and myocardial injury in patients admitted to the emergency department. We analyzed the clinical data of all consecutive patients admitted to the emergency department during the years 2012 and 2013 with at least 1 cardiac Troponin I (cTnI Ultra Siemens, Advia Centaur) determination, and were classified according to the status of diabetes mellitus (DM) and myocardial injury (MI). Clinical events were evaluated in a 4-year follow-up. A total of 3622 patients were classified according to the presence of DM (n = 924 (25.55%)) and MI (n = 1049 (28.96%)). The proportion of MI in patients with DM was 40% and 25% in patients without DM. Mortality during follow-up was 10.9% in non-DM patients without MI, 21.3% in DM patients without MI, 40.1% in non-DM patients with MI, and 52.8% in DM patients with MI. A competitive risk model was used to obtain the Hazard Ratio (HR) for readmission for myocardial infarction or heart failure. There was a similar proportion of readmission for myocardial infarction and heart failure at a four-year follow-up in patients with DM or MI, which was much higher when DM was associated with MI, with respect to patients without DM or MI. The HR (95% Coefficient Interval) for myocardial infarction in the DM without MI, non-DM with MI, and DM with MI groups with respect to the non-DM without MI group was 2511 (1592-3960), 2682 (1739-4138), and 5036 (3221-7876), respectively. The HR (95% CI) for the risk of readmission for heart failure in the DM without MI, non-DM with MI, and DM with MI groups with respect to the non-DM without MI group was 2663 (1825-3886), 2562 (1753-3744) and 4292 (2936-6274), respectively. The association of DM and MI in patients treated in an Emergency Service identifies patients at very high risk of mortality and cardiovascular events.

Sections du résumé

BACKGROUND
This study aimed to investigate the clinical features and prognosis of diabetes and myocardial injury in patients admitted to the emergency department.
METHODS
We analyzed the clinical data of all consecutive patients admitted to the emergency department during the years 2012 and 2013 with at least 1 cardiac Troponin I (cTnI Ultra Siemens, Advia Centaur) determination, and were classified according to the status of diabetes mellitus (DM) and myocardial injury (MI). Clinical events were evaluated in a 4-year follow-up.
RESULTS
A total of 3622 patients were classified according to the presence of DM (n = 924 (25.55%)) and MI (n = 1049 (28.96%)). The proportion of MI in patients with DM was 40% and 25% in patients without DM. Mortality during follow-up was 10.9% in non-DM patients without MI, 21.3% in DM patients without MI, 40.1% in non-DM patients with MI, and 52.8% in DM patients with MI. A competitive risk model was used to obtain the Hazard Ratio (HR) for readmission for myocardial infarction or heart failure. There was a similar proportion of readmission for myocardial infarction and heart failure at a four-year follow-up in patients with DM or MI, which was much higher when DM was associated with MI, with respect to patients without DM or MI. The HR (95% Coefficient Interval) for myocardial infarction in the DM without MI, non-DM with MI, and DM with MI groups with respect to the non-DM without MI group was 2511 (1592-3960), 2682 (1739-4138), and 5036 (3221-7876), respectively. The HR (95% CI) for the risk of readmission for heart failure in the DM without MI, non-DM with MI, and DM with MI groups with respect to the non-DM without MI group was 2663 (1825-3886), 2562 (1753-3744) and 4292 (2936-6274), respectively.
CONCLUSIONS
The association of DM and MI in patients treated in an Emergency Service identifies patients at very high risk of mortality and cardiovascular events.

Identifiants

pubmed: 34461832
doi: 10.1186/s12872-021-02220-1
pii: 10.1186/s12872-021-02220-1
pmc: PMC8404360
doi:

Substances chimiques

Biomarkers 0
Troponin I 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

414

Informations de copyright

© 2021. The Author(s).

Références

J Clin Med. 2020 Dec 02;9(12):
pubmed: 33276667
Diabetes Care. 2020 Oct;43(10):e144-e146
pubmed: 32788284
Cardiovasc Diabetol. 2012 Dec 27;11:154
pubmed: 23270513
Am J Med. 2019 May;132(5):614-621
pubmed: 30571931
N Engl J Med. 2015 Aug 13;373(7):610-20
pubmed: 26267622
J Am Coll Cardiol. 2006 Oct 17;48(8):1688-97
pubmed: 17045908
Nutr Metab (Lond). 2017 Nov 25;14:73
pubmed: 29204182
Nature. 2001 Dec 13;414(6865):813-20
pubmed: 11742414
Am Heart J. 2016 Apr;174:43-50
pubmed: 26995369
Cardiovasc Diabetol. 2018 Jun 8;17(1):83
pubmed: 29884191
Circulation. 2011 Jun 21;123(24):2811-8
pubmed: 21632491
Rev Esp Cardiol (Engl Ed). 2015 Jun;68(6):469-76
pubmed: 25800165
Circulation. 2015 Aug 25;132(8):691-718
pubmed: 26246173
BMC Cardiovasc Disord. 2015 Jul 21;15:72
pubmed: 26195004
Diabetes Care. 2020 Jan;43(Suppl 1):S111-S134
pubmed: 31862753
Cardiovasc Diabetol. 2010 Sep 15;9:52
pubmed: 20843304
J Diabetes Metab Disord. 2019 Nov 11;18(2):693-704
pubmed: 31890693
J Am Coll Cardiol. 2012 Jan 31;59(5):484-9
pubmed: 22281251
Lancet Diabetes Endocrinol. 2015 Feb;3(2):105-13
pubmed: 25466521
J Endocr Soc. 2018 Jul 19;2(9):1020-1023
pubmed: 30187014
J Nippon Med Sch. 2015;82(6):274-80
pubmed: 26823030
Circulation. 2017 May 16;135(20):1911-1921
pubmed: 28246236
Cardiovasc Diabetol. 2014 Mar 25;13:63
pubmed: 24661773
JACC Heart Fail. 2021 Mar;9(3):215-223
pubmed: 33422434
Int J Cardiol. 2017 Dec 1;248:301-307
pubmed: 28802735
Am J Med. 2014 Apr;127(4):295-302
pubmed: 24457000
JAMA Cardiol. 2016 Dec 1;1(9):989-998
pubmed: 27681000
Heart. 2017 Apr;103(8):616-622
pubmed: 27742797

Auteurs

Gil Bonet (G)

Department of Cardiology, Joan XXIII University Hospital, Calle Dr Mallafré Guash 4, 43005, Tarragona, Spain.
Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.
Rovira I Virgili University, Tarragona, Spain.

Anna Carrasquer (A)

Department of Cardiology, Joan XXIII University Hospital, Calle Dr Mallafré Guash 4, 43005, Tarragona, Spain.
Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.
Rovira I Virgili University, Tarragona, Spain.

Óscar M Peiró (ÓM)

Department of Cardiology, Joan XXIII University Hospital, Calle Dr Mallafré Guash 4, 43005, Tarragona, Spain.
Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.
Rovira I Virgili University, Tarragona, Spain.

Raul Sanchez-Gimenez (R)

Department of Cardiology, Joan XXIII University Hospital, Calle Dr Mallafré Guash 4, 43005, Tarragona, Spain.
Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.
Rovira I Virgili University, Tarragona, Spain.

Nisha Lal-Trehan (N)

Department of Cardiology, Joan XXIII University Hospital, Calle Dr Mallafré Guash 4, 43005, Tarragona, Spain.
Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.
Rovira I Virgili University, Tarragona, Spain.

Victor Del-Moral-Ronda (V)

Department of Cardiology, Joan XXIII University Hospital, Calle Dr Mallafré Guash 4, 43005, Tarragona, Spain.
Pere Virgili Health Research Institute (IISPV), Tarragona, Spain.
Rovira I Virgili University, Tarragona, Spain.

Isabel Fort-Gallifa (I)

Clinical Laboratory, Catalan Institute of Health, Camp de Tarragona-Terres de L'Ebre, Tarragona, Spain.

Alfredo Bardají (A)

Department of Cardiology, Joan XXIII University Hospital, Calle Dr Mallafré Guash 4, 43005, Tarragona, Spain. alfredo.bardaji@urv.cat.
Pere Virgili Health Research Institute (IISPV), Tarragona, Spain. alfredo.bardaji@urv.cat.
Rovira I Virgili University, Tarragona, Spain. alfredo.bardaji@urv.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH